Cue Biopharma Inc
NASDAQ:CUE

  • LAST PRICE
    1.7100
  • TODAY'S CHANGE (%)
    -0.0300 (-1.7241%)
  • Bid / Lots
    1.6500/ 6
  • Ask / Lots
    1.8000/ 1
  • Open / Previous Close
    1.7400 / 1.7400
  • Day Range
    1.6600
    1.7700
  • 52 Week Range
    1.3027
    4.8900
  • Volume
    117,895

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • May 9, 2024

      Show headlines and story abstract

    • 4:05PM ET on Thursday May 09, 2024 by GlobeNewswire
      Companies Mentioned: CUE

    • 4:05PM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: CUE

      submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

    • 4:05PM ET on Thursday May 09, 2024 by Dow Jones
      Companies Mentioned: CUE

      submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the future and ability to continue as a going concern; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

  • May 8, 2024

Peers Headlines